Please login to the form below

Not currently logged in
Email:
Password:

WuXi PharmaTech potential USD 184.7m IPO

China-headquartered pharmaceutical and biotech company WuXi PharmaTech has released its initial public offering of 13,188,979 American Depositary Shares

China-headquartered pharmaceutical and biotech company WuXi PharmaTech (WuXi) has released its initial public offering (IPO) of 13,188,979 American Depositary Shares (ADSs).

Of the 13,188,979 ADSs sold in the offering, 10,000,000 ADSs were sold by WuXi, while 3,188,979 ADSs were sold by selling shareholders. The company has granted the underwriters a 30-day option to purchase up to an additional 1,978,347 ADSs to cover over-allotments.

WuXi says it should raise USD 107.8m from the sale, or USD 129.9m if underwriters exercise their options. The firm plans to use USD 40m to expand its Jingsu facility, USD 40m to build a new centre in Suzhou and the rest for general corporate purposes.

Each ADS represents eight ordinary shares and was priced at USD 14.00 per ADS. The ADSs will begin trading on the New York Stock Exchange on 9 August 2007 under the symbol 'WX.'

Credit Suisse Securities and J P Morgan Securities acted as representatives of the underwriters and joint book runners, while Jefferies & Company acted as co-manager for the offering.

WuXiís net revenue for Q1 FY07 rose 165 per cent on Q1 FY06 figures to rest at USD 33.8m. Net income was USD 6m, excluding pre-IPO stock compensation.

9th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...
NHS Long Term Plan - Digital is firmly on the agenda. Are you ready?
The message is clear. To keep pace with the NHS, pharma and healthcare companies must act now and refine their digital strategy to meet the needs of a transforming NHS....

Infographics